GLOBAL
IRRITABLE BOWEL SYNDROME TEATMENT MARKET Market Size (2019)
US$ 1,044.9 MN CAGR (2019 – 2027)
12.9%
© Coherent Market Insights. All Rights Reserved
Segmentation (Scope)
By Medical Condition
By Drug Type
By Distribution Channel
IBS-constipation
Lubiprostone
Hospital Pharmacies
IBS-diarrhea
Linaclotide
Online Pharmacies
Eluxadoline
Retail Pharmacies
Rifaximin
Alosetron
Others © Coherent Market Insights. AllAll Rights Reserved © Coherent Market Insights. Rights Reserved
Major Drivers Increasing launches and regulatory approvals Increase in the adoption of inorganic strategies by the manufacturers © Coherent Market Insights. AllAll Rights Reserved © Coherent Market Insights. Rights Reserved
NORTH AMERICA
ASIA PACIFIC
Market Size (2019)
Market Size (2019)
US$ 356.3 MN
US$ 241.3 MN
CAGR
CAGR
9.1%
13.3%
Major Drivers
Major Drivers
Increased prevalence of irritable bowel syndrome among the population Increase in research and development of new therapeutic products for treatment of IBS
Increasing adoption of inorganic strategies by manufacturers to expand their presence in the region Increasing prevalence of irritable bowel syndrome among the population © Coherent © Coherent Market Insights. AllAll Rights Reserved Market Insights. Rights Reserved
Major Players Abbott Laboratories Astellas Pharma Inc. Bausch Health Companies Novartis AG Mallinckrodt plc. GlaxoSmithKline plc. Ardelyx, Inc. Luoxin Pharmaceutical Group Co., Ltd. Alfasigma USA, Inc. Ironwood Pharmaceuticals Inc.
© Coherent Market Insights. AllAll Rights Reserved © Coherent Market Insights. Rights Reserved